integument
• frequency and number of dendritic epidermal T cells are reduced in imiquimod-treated skin
|
• mice show reduced susceptibility to imiquimod-induced psoriasis, with mice showing decreased thickness, scaling, erythema, and inflammatory response on the ear skin treated with imiquimod
• ears treated with imiquimod show decreased acanthosis and hyperkeratosis, with inhibited accumulation of immune cells
|
immune system
• frequency and cell count of infiltrating alpha-beta T cells are increased in imiquimod-treated skin
|
• frequency and cell count of infiltrating gamma-delta T cells are increased in imiquimod-treated skin
|
• mice treated with imiquimod show a decrease in the absolute number of white blood cells in treated skin
|
• mice treated with imiquimod show lower frequencies and absolute number of plasmacytoid dendritic cells in lesioned skin, spleen, and draining lymph nodes, however no differences in levels in the blood are seen
|
• frequency and number of dendritic epidermal T cells are reduced in imiquimod-treated skin
|
• expression of the T cell activation maker CD44 is decreased in alpha-beta T, gamma-delta T, and dendritic epidermal T cells of imiquimod-treated skin
|
• mice treated with imiquimod show decreased mRNA expression levels of pro-inflammatory cytokines, including IFN-alpha, TNF-alpha, IL-23, and IL-17a, in treated ear skin
|
• expression of IFN-alpha in imiquimod-treated ear skin is reduced by as much as 23-fold
|
• expression of IL-23 and IL-17a in imiquimod-treated ear skin is reduced
|
• expression of TNF-alpha in imiquimod-treated ear skin is reduced
|
• expression of the plasmacytoid dendritic cell activation maker CD80 is decreased in imiquimod-treated lesioned skin
|
• mice show reduced susceptibility to imiquimod-induced psoriasis, with mice showing decreased thickness, scaling, erythema, and inflammatory response on the ear skin treated with imiquimod
• ears treated with imiquimod show decreased acanthosis and hyperkeratosis, with inhibited accumulation of immune cells
|
homeostasis/metabolism
• mice treated with imiquimod show decreased mRNA expression levels of pro-inflammatory cytokines, including IFN-alpha, TNF-alpha, IL-23, and IL-17a, in treated ear skin
|
• expression of IFN-alpha in imiquimod-treated ear skin is reduced by as much as 23-fold
|
• expression of IL-23 and IL-17a in imiquimod-treated ear skin is reduced
|
• expression of TNF-alpha in imiquimod-treated ear skin is reduced
|
hematopoietic system
• frequency and cell count of infiltrating alpha-beta T cells are increased in imiquimod-treated skin
|
• frequency and cell count of infiltrating gamma-delta T cells are increased in imiquimod-treated skin
|
• mice treated with imiquimod show a decrease in the absolute number of white blood cells in treated skin
|
• mice treated with imiquimod show lower frequencies and absolute number of plasmacytoid dendritic cells in lesioned skin, spleen, and draining lymph nodes, however no differences in levels in the blood are seen
|
• frequency and number of dendritic epidermal T cells are reduced in imiquimod-treated skin
|
• expression of the T cell activation maker CD44 is decreased in alpha-beta T, gamma-delta T, and dendritic epidermal T cells of imiquimod-treated skin
|